drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous CD19-directed CAR T-cell therapy; engineered T cells target CD19+ B cells (naive, memory, plasmablasts) to deplete autoreactive B-cell compartments and reduce autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting CD19, enabling recognition and cytotoxic elimination of CD19+ B cells (naive, memory, plasmablasts). This depletes autoreactive B-cell compartments, reduces autoantibody production, and dampens B cell–driven immune inflammation.
drug_name
CABA-201 (resecabtagene autoleucel; Rese-cel)
nct_id_drug_ref
NCT06154252